Sulodeksyd – wskazania do stosowania Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2019
Słowa kluczowe:
sulodeksyd, wskazania, przewlekła niewydolność żylna, niewydolność tętnicza, żylna choroba zakrzepowo-zatorowa, profilaktyka
##plugins.themes.bootstrap3.article.main##
Abstrakt
Sulodeksyd to lek pod względem budowy chemicznej przypominający heparynę. Ma działanie przeciwzakrzepowe, profibrynolityczne, przeciwzapalne i protekcyjne na śródbłonek naczyniowy. Stosuje się go w leczeniu schorzeń zakrzepowo-zatorowych łożyska żylnego i tętniczego. Poprawia gojenie owrzodzeń podudzi u pacjentów z niewydolnością żylną i tętniczą. Ogranicza także ryzyko nawrotów zakrzepicy w przedłużonej prewencji wtórnej żylnej choroby zakrzepowo- zatorowej.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Okopień, B., Maligłówka, M., & Anton, M. (2019). Sulodeksyd – wskazania do stosowania . Medycyna Faktów , 12(3(44), 246-249. https://doi.org/10.24292/01.MF.0319.10
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Pisano L., Moronesi F., Falco F. et al.: The use of sulodexide in the treatment of peripheral vasculopathy accompanying metabolic diseases. Controlled study in hyperlipidemic and diabetic subjects. Thromb. Res. 1986; 41(1): 23-31.
2. Elmi G., Di Pasquale G., Pesavento R.: The optimal duration of anticoagulant therapy after unprovoked venous thromboembolism – still a challenging issue. Vasa 2017; 46(2): 87-95.
3. Vessel Due F – charakterystyka produktu leczniczego.
4. Carroll B.J., Piazza G., Goldhaber S.Z.: Sulodexide in venous disease. J. Thromb. Haemost. 2019; 17(1): 31-38.
5. Raffetto J.D.: Pathophysiology of Chronic Venous Disease and Venous Ulcers. Surg. Clin. North Am. 2018; 98(2): 337-347.
6. Becker B.F., Jacob M., Leipert S. et al.: Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br. J. Clin. Pharmacol. 2015; 80(3): 389-402.
7. Cospite M., Ferrara F., Cospite V., Palazzini E.: Sulodexide and the microcirculatory component in microphlebopathies. Curr. Med. Res. Opin. 1992; 13(1): 56-60.
8. Elleuch N., Zidi H., Bellamine Z. et al.: Sulodexide in Patients with Chronic Venous Disease of the Lower Limbs: Clinical Efficacy and Impact on Quality of Life. Adv Ther. 2016; 33(9): 1536-1549.
9. Patton L.R.: Are community leg ulcer clinics more cost-effective than home care visits? J. Wound Care. 2009; 18(2): 49-50, 52.
10. Serra R., Buffone G., Costanzo G. et al.: Varicocele in younger as risk factor for inguinal hernia and for chronic venous disease in older: preliminary results of a prospective cohort study. Ann. Vasc. Surg. 2013; 27(3): 329-331.
11. Wu B., Lu J., Yang M., Xu T.: Sulodexide for treating venous leg ulcers. Cochrane Wounds Group, editor. Cochrane Database Syst. Rev. [Internet]. 2016 Jun 2 [cited 2019 Mar 27] [online].
12. Serra R., Gallelli L., Conti A. et al.: The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs. Drug Des. Devel. Ther. 2014: 519.
13. Giannotti G., Landmesser U.: Endothelial dysfunction as an early sign of atherosclerosis. Herz. 2007; 32(7): 568-572.
14. Sosińska P., Baum E., Maćkowiak B. et al.: Sulodexide Reduces the Proinflammatory Effect of Serum from Patients with Peripheral Artery Disease in Human Arterial Endothelial Cells. Cell Physiol. Biochem. 2016; 40(5): 1005-1012.
15. Sosińska-Zawierucha P., Maćkowiak B., Staniszewski R. et al.: Sulodexide Slows Down the Senescence of Aortic Endothelial Cells Exposed to Serum from Patients with Peripheral Artery Diseases. Cell Physiol. Biochem. 2018; 45(6): 2225-2232.
16. Cosmi B.: Management of idiopathic venous thromboembolism. Expert Rev. Cardiovasc. Ther. 2016; 14(12): 1371-1384.
17. Andreozzi G.M., Bignamini A.A., Davì G. et al.: Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Circulation 2015; 132(20): 1891-1897.
18. Broekhuizen L.N., Lemkes B.A., Mooij H.L. et al.: Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53(12): 2646-2655.
19. Olde Engberink R.H.G., Heerspink H.J.L., de Zeeuw D., Vogt L.: Blood pressure-lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies: Sulodexide lowers BP in diabetic nephropathy. Br. J. Clin. Pharmacol. 2016; 82(5): 1351-1357.
20. Olde Engberink R.H.G., Rorije N.M.G, Lambers Heerspink H.J. et al.: The blood pressure lowering potential of sulodexide – a systematic review and meta-analysis: Sulodexide and blood pressure. Br. J. Clin. Pharmacol. 2015; 80(6): 1245-1253.
2. Elmi G., Di Pasquale G., Pesavento R.: The optimal duration of anticoagulant therapy after unprovoked venous thromboembolism – still a challenging issue. Vasa 2017; 46(2): 87-95.
3. Vessel Due F – charakterystyka produktu leczniczego.
4. Carroll B.J., Piazza G., Goldhaber S.Z.: Sulodexide in venous disease. J. Thromb. Haemost. 2019; 17(1): 31-38.
5. Raffetto J.D.: Pathophysiology of Chronic Venous Disease and Venous Ulcers. Surg. Clin. North Am. 2018; 98(2): 337-347.
6. Becker B.F., Jacob M., Leipert S. et al.: Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br. J. Clin. Pharmacol. 2015; 80(3): 389-402.
7. Cospite M., Ferrara F., Cospite V., Palazzini E.: Sulodexide and the microcirculatory component in microphlebopathies. Curr. Med. Res. Opin. 1992; 13(1): 56-60.
8. Elleuch N., Zidi H., Bellamine Z. et al.: Sulodexide in Patients with Chronic Venous Disease of the Lower Limbs: Clinical Efficacy and Impact on Quality of Life. Adv Ther. 2016; 33(9): 1536-1549.
9. Patton L.R.: Are community leg ulcer clinics more cost-effective than home care visits? J. Wound Care. 2009; 18(2): 49-50, 52.
10. Serra R., Buffone G., Costanzo G. et al.: Varicocele in younger as risk factor for inguinal hernia and for chronic venous disease in older: preliminary results of a prospective cohort study. Ann. Vasc. Surg. 2013; 27(3): 329-331.
11. Wu B., Lu J., Yang M., Xu T.: Sulodexide for treating venous leg ulcers. Cochrane Wounds Group, editor. Cochrane Database Syst. Rev. [Internet]. 2016 Jun 2 [cited 2019 Mar 27] [online].
12. Serra R., Gallelli L., Conti A. et al.: The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs. Drug Des. Devel. Ther. 2014: 519.
13. Giannotti G., Landmesser U.: Endothelial dysfunction as an early sign of atherosclerosis. Herz. 2007; 32(7): 568-572.
14. Sosińska P., Baum E., Maćkowiak B. et al.: Sulodexide Reduces the Proinflammatory Effect of Serum from Patients with Peripheral Artery Disease in Human Arterial Endothelial Cells. Cell Physiol. Biochem. 2016; 40(5): 1005-1012.
15. Sosińska-Zawierucha P., Maćkowiak B., Staniszewski R. et al.: Sulodexide Slows Down the Senescence of Aortic Endothelial Cells Exposed to Serum from Patients with Peripheral Artery Diseases. Cell Physiol. Biochem. 2018; 45(6): 2225-2232.
16. Cosmi B.: Management of idiopathic venous thromboembolism. Expert Rev. Cardiovasc. Ther. 2016; 14(12): 1371-1384.
17. Andreozzi G.M., Bignamini A.A., Davì G. et al.: Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Circulation 2015; 132(20): 1891-1897.
18. Broekhuizen L.N., Lemkes B.A., Mooij H.L. et al.: Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53(12): 2646-2655.
19. Olde Engberink R.H.G., Heerspink H.J.L., de Zeeuw D., Vogt L.: Blood pressure-lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies: Sulodexide lowers BP in diabetic nephropathy. Br. J. Clin. Pharmacol. 2016; 82(5): 1351-1357.
20. Olde Engberink R.H.G., Rorije N.M.G, Lambers Heerspink H.J. et al.: The blood pressure lowering potential of sulodexide – a systematic review and meta-analysis: Sulodexide and blood pressure. Br. J. Clin. Pharmacol. 2015; 80(6): 1245-1253.